The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

March 22, 2007 07:41 ET

Medipattern Announces Integration with Sectra

B-CAD™ Integrated onto Sectra's Multi-Modality Breast Imaging Workstation

TORONTO, ONTARIO--(CCNMatthews - March 22, 2007) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided diagnosis (CAD) solutions for medical imaging, whose mission is to reduce the number of unnecessary biopsies performed to diagnose cancer, is pleased to announce the integration of B-CAD with Sectra's breast imaging workstation. The Swedish IT and medical technology company Sectra is one of the world's major diagnostic imaging system (PACS) providers, Sectra's workstation brings together images from multiple modalities, including mammography, breast ultrasound, and breast MRI, for a complete patient review on one platform. An efficient workflow is created by gathering all of the functionality required to interpret the complete breast imaging case from screening through treatment planning stages. Both the Sectra workstation and Medipattern B-CAD are released and have received global clearances for immediate shipment.

"For the benefit of our customers we include highly specialized clinical applications into our products. Sectra is among the first to include B-CAD functionality in a PACS environment and with Medipattern, we can now offer the ability to perform CAD on ultrasound breast imaging," said Mischa Woisetschlager, Ph.D., Global Product Manager of Clinical Applications for Sectra."

The integrated solution enhances workflow and reduces read-to-report time. In addition, B-CAD's high level of detail in reporting provides strong evidence leading to increased diagnostic confidence in support of follow-up between breast exams.

B-CAD segments a lesion and automatically reviews key features to characterize it. B-CAD then uses radiologists' input along with the American College of Radiology's BI-RADS® feature category and descriptor checklists to generate a BI-RADS® score for the lesion, providing consistency in results and making it possible to follow a benign lesion from visit to visit. Finally, B-CAD records all of the findings automatically and generates a structured report in natural language.

"Sectra's unique open interface and interoperability between all of the types of imaging used to detect, diagnose, plan, and track patient progress through breast cancer treatment creates a total treatment planning center. This positions Sectra as a full-scale provider to the global market place," said Jeff Collins, CEO of Medipattern. "We look forward to being able to provide CAD for breast ultrasound to all of Sectra's current and future customers."

Upcoming Events:

Medipattern will participate in the following events:

- Society of Breast Imaging, April 14 to 17 2007 in Hollywood Florida.

- China MED 2007, April 22 to 24, Beijing, PRC.

- American Society of Breast Surgeons Annual Meeting, May 2 to 7, 2007 Phoenix, AZ.

- Breast Imaging Course sponsored by Stanford, May 2 to 6 in Las Vegas, NV.

- Chicago International Breast Imaging Symposium October 3 to 7, 2007, Chicago, IL.

- RSNA, November 25 to 29, 2007, Chicago, IL.

About Sectra

Sectra is one of the world's major diagnostic imaging system (PACS) providers. More than 900 hospitals worldwide use the system daily and more than 40 million radiology examinations are diagnosed in Sectra's system annually. In Scandinavia, Sectra is the market leader with more than 50% of all film-free installations. Sectra's systems have been installed in North America, Scandinavia and most major countries in Europe and the Far East.

Sectra successfully develops and sells cutting edge products in the expansive niche segments of medical systems and secure communication systems. The company was founded in 1978 and has its roots in Linkoping Institute of Technology in Sweden. Today, Sectra has offices in eleven countries and operates through partners worldwide. Sales in the 2005/2006 fiscal year totaled SEK 564 million. Since 1999, the Sectra share is quoted on the Nordic Exchange. For more information about Sectra visit www.sectra.se.

About The Medipattern Corporation

Medipattern develops computer-aided diagnosis (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CAD MRI™. Both have received awards for innovation in the industry. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Medipattern was founded to design software products that save lives, detect breast cancer, and reduce the number of unnecessary biopsies in women referred for diagnosis of potential breast cancer. Please visit the company's website at: www.medipattern.com.

About B-CAD™

B-CAD, a computer-assisted diagnosis software system, segments a selected breast lesion and automatically reviews key features to characterize it. B-CAD then uses radiologists' input along with the American College of Radiology's BI-RADS® (Breast Imaging Report and Data System) feature category and descriptor checklists to generate a BI-RADS® score for each lesion, providing consistency in results and making it possible to follow a lesion from visit to visit. Finally, B-CAD records all of the findings automatically and generates a structured report in natural language.

B-CAD™ and B-CAD MRI™ are trademarks of The Medipattern Corporation.
Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information